of surfactants, fatty acids, bile salts, chelating agents, non-chelating non-surfactant molecules, and combinations thereof;

wherein said oligonucleotide is selected from the group consisting of a molecular decoy, an external guide sequence and an aptamer.

28. (New) The composition of claim 27 further comprising a carrier compound, wherein said carrier compound is selected from the group consisting of lipofectin, cationic glycerol derivatives and polylysine.

29. (New) A composition comprising an oligonucleotide in oral dosage form, wherein said oligonucleotide comprises at least one modified covalent linkage and wherein said oligonucleotide is selected from the group consisting of an external guide sequence, a molecular decoy and an aptamer.

30. (New) A composition comprising an oligonucleotide in oral dosage form and an enteric material that substantially prevents dissolution of a tablet or capsule in a mammalian stomach;

wherein said oligonucleotide comprises at least one modified covalent linkage;

wherein said oral dosage form is a tablet or capsule; and

wherein said enteric material is selected from the group consisting of cellulose acetate trimellitate, hydroxy propyl methyl cellulose phthalate and cellulose acetate phthalate.